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Asthma is a chronic inflammatory disease of the airways in which the majority of patients 
respond to treatment with corticosteroids and β2 adrenoceptor agonists. Acute exacerbations 
of asthma substantially contribute to disease morbidity, mortality and health care costs, and 
are not restricted to patients who are noncompliant with their treatment regimens. Given that 
respiratory viral infections are the principal cause of asthma exacerbations, this review article 
will explore the relationship between viral infections and asthma, and will put forward 
hypotheses as to why virus induced exacerbations occur.  Potential mechanisms that may 
explain why current therapeutics do not fully inhibit virus-induced exacerbations, for 
example β2 adrenergic desensitisation and corticosteroid insensitivity, are explored, as well 
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1.  Introduction 
Asthma is an intriguing disease that is perhaps best thought of as a series of overlapping 
aberrant biological processes which ultimately result in airway inflammation and 
characteristic airway physiology. Whilst inflammation is a hallmark feature of asthma, 
asthmatic inflammation is not homogeneous. This is exemplified in studies which have 
measured granulocytes in induced sputum. In such studies asthmatic pathology can be 
classified as eosinophilic, neutrophilic, mixed or paucigranulocytic (neither) [1]. Altered 
airways function is manifest in symptoms such as shortness of breath, cough, and wheeze and 
is characterised physiologically by airways hyperresponsiveness (AHR). AHR represents 
airways contraction in response to concentrations of agonists which are without effect in the 
non-asthmatic, together with reversible airflow limitation. Fortunately, even with the 
heterogeneity which exists in the various clinical and biological phenotypes of asthma, 
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corticosteroids and β2 adrenoceptor agonists are clinically useful therapies for the majority of 
patients. However, even though symptoms can be well controlled for long periods of time by 
corticosteroids and β2 agonists, viral respiratory tract infections can cause symptom relapse 
or exacerbations. The reason(s) why viruses cause exacerbations of asthma is not known- 
simplistically, viral infection could contribute to asthma symptoms and/or change airways 
physiology. The purpose of this review is to put forward hypotheses as to why virus induced 
exacerbations occur, and to discuss potential mechanisms that may explain why current 
therapeutics do not fully inhibit virus-induced exacerbations.  
 
2.  Asthma 
Asthma is a chronic lung disease in which corticosteroids are used to control airway 
inflammation and β2 agonists provide bronchodilatation. These are the most effective current 
treatments for asthma and, when taken concomitantly, their efficacy is generally increased. In 
the absence of any exacerbants (ie a stimulant which causes symptom control to relapse), 
optimal treatment reduces asthma symptoms, peak expiratory flow variability and indices of 
inflammation. Exacerbations are characterised by worsening asthma symptoms and a fall in 
lung function, and contribute substantially to the cost and burden of asthma. For example in 
New South Wales (a state of Australia with a population of around 7 million) there were 
22,942 emergency department visits for asthma, of which 42% were admitted to hospital in 
2007 [2]. The annual cost per person for hospital admissions can reach ≈ €15,000. In addition 
to the direct medical costs, the costs of absenteeism from work / school are thought to 
account for 50% of the total cost of treating asthma. Whilst the majority of asthma 
exacerbations occur in those who are non-compliant with medication usage, it is important to 
note that viruses can cause even the well controlled patient to exacerbate [3].  
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3. Viruses and Asthma 
There is overwhelming evidence demonstrating the association of asthma 
exacerbations with viral infections in the community. Johnston and colleagues were amongst 
the first to show the extent and ramifications of viral infections in asthmatic school children 
using polymerase chain reaction (PCR) techniques in combination with other well established 
viral detection methods. In this seminal study, 108 children aged between 9 and 11 years old 
were monitored by peak flow measurements, and viral sampling was obtained during 
symptomatic episodes. Viruses were isolated in 77% of episodes, of which picornavirus was 
the predominant virus identified (147 episodes, 50%). Coronaviruses were the second most 
prevalent, being isolated in 38 episodes (13%), parainfluenza and influenza were isolated in 
21 episodes (7%) each and respiratory syncytial virus (RSV) was isolated in 12 episodes 
(4%).  Rhinovirus was found to be the predominant virus within the picornavirus group, as it 
was identified in 84 episodes, whilst relatively few had more than two different viruses 
detected (5%) [4]. In comparison to children, a similar proportion (80%) of adults has been 
shown to have a viral infection at the time of episodic asthma worsening [5], however others 
have found lower detection rates of virus in adults [6, 7]. Several reasons may account for 
this discrepancy. The time taken for adults to present with symptoms could be longer in 
comparison to that in children, virus replication may be reduced and/or greater clearance may 
occur in adults.  
Whilst the association of viral infections and exacerbations of asthma is clearly 
defined, the role of viral infections in the aetiology of asthma itself is more controversial. 
Several studies have suggested a causal role, as outlined below. However, given the fact that 
both RSV and rhinovirus are particularly promiscuous in infants, infecting 80-90 % of all 
children by the time they reach two years of age [8, 9], a simple cause and effect hypothesis 
does not hold. Two long term follow up studies have both demonstrated sequelae from severe 
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RSV infection early in life (defined as requiring hospitalisation) at entry to adulthood: Korppi 
et al demonstrated deficits in lung function following RSV in the first two years of life, whilst 
Sigurs et al have shown increased rates of asthma (not found in the studies of Korppi et al) in 
a cohort requiring hospitalisation in the first six months of life [10]. Milder RSV infection up 
to the age of three in the Tucson birth cohort was associated with increased risk of wheeze up 
to 11 years of age [11]. The association between RSV infection and the subsequent 
development of asthma appears to change with age. A recent meta-analysis found that the 
attributable risk of developing asthma following RSV infection was 13% to 22% in children 
five and under, 11% to 27% in children aged 5 to 11, and was 32% in children twelve and 
older [12]. More recent data from the Childhood Origins of ASThma (COAST) cohort 
suggest a stronger association between rhinovirus and subsequent asthma risk. In this 
prospective study in a cohort of 259 children, rhinovirus infection was highly associated with 
the development of wheeze at three years and asthma at six years of age, (odds ratio 
approximately 10) [13, 14]. When virus -induced wheeze up to age three was correlated to 
the presence of asthma at six years of age, the odds ratio reported for rhinovirus was almost 
four times that of RSV (odds ratio 9.8 vs. 2.6), and reached 10 for both viruses taken 
together. This suggests a more important etiological role for rhinovirus than RSV, and is 
echoed by other studies describing the impact of rhinovirus in this early childhood setting 
[12, 15, 16]. Many confounding factors influence the validity of such results. The frequency 
of asthma in the community is greater in children than in adults but asthma can develop later 
in life. Therefore when studies are carried out examining effects of viral infection in infancy 
upon the development of asthma at static time-points, it is plausible that the estimations of 
causality are inaccurate.  
The timing and frequency of viral infections may also be important. Infancy 
represents a rapid period of growth for both the immune system and lung development. 
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During this “susceptibility” period, viral infections may have their largest impact [17]. 
Infants experiencing viral seasons (e.g. RSV) during the first six months of life have a higher 
prevalence of asthma [18, 19]. Animal studies have shown that early viral insults can affect 
the immune system with long lasting effects on immune and pulmonary function [20, 21]. 
The importance of frequency of lower respiratory tract infection is suggested by data from 
the German Multicentre Allergy Study, which followed 1314 children from birth to 13 years 
of age [22].  Children who had more than one viral infection of the upper respiratory tract 
(defined by a runny nose) during the first year of life had a decreased likelihood of 
developing asthma at age 7, whilst in the same study, children who had two or more 
(evidence more powerful for four or more) lower respiratory tract infections during the first 3 
years of life were at a greater risk of developing asthma at age 7 [22].  
The alternate explanation for such studies is that these early viral infections are 
simply the first marker of an underlying predisposition to asthma, due to abnormal lung 
function and/or genetic factors, rather than a key insult in the development of asthma [17]. 
Studies attempting to answer this question have produced conflicting results to date [23, 24], 
although a recent analysis of two large separate birth cohorts (COAST study and Copenhagen 
perspective study on asthma in childhood) identified a virus specific association between 
genetic variation at the 17q21 locus, RV induced wheezing illness and childhood asthma 
[25]. To date there is no clear evidence that there is a true increased susceptibility to infection 
in these individuals. However, there are several other important factors that appear to modify 
subsequent asthma risk in these young children. The German Multicentre Allergy Study 
showed that it was the presence of early atopic sensitization in the first few years of life that 
influenced subsequent asthma outcomes[26]. Kusel et al demonstrated in a smaller cohort of 
almost 200 children, followed from birth to five years, that the presence of sensitisation early 
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on (at or before the age of two years) appeared to magnify the risk associated with viral 
infection of subsequent asthma [27].  
The current view is that development of asthma in childhood is multifactorial, 
reflecting both genetic predisposition and multiple environmental exposures occurring at 
critical time points as the child develops. These include viral respiratory infections [28, 29], 
delayed immune system maturation [30], and allergic sensitization [27]. The temporal 
relationship between these factors is unclear. The genetic composition of an individual may 
also bias such experiments. A maternal history of asthma increases the risk of severe lower 
respiratory tract infection during the first year of life, independent of the risk of developing 
asthma. Recent data have shown that better maternal asthma control during pregnancy is 
associated with a significant decrease in the number of episodes of bronchiolitis occurring 
during infancy [31]. Similarly, a maternal history of bronchiolitis increases the risk of 
childhood lower respiratory tract infections [32]. In children who wheeze post bronchiolitis 
there is increased occurrence of genetic polymorphisms in the interleukin (IL)-8 gene, both in 
comparison to non-wheezers and the general population [33]. Attempts to investigate the 
effect of associations between virus infection and the host immune system on subsequent 
asthma development or exacerbations in those with pre-existing asthma, often focus upon a 
single viral type, and may possibly overlook the role of multiple concurrent infections. Given 
that the frequency of two concomitant  respiratory viral infections is around 20-30%, [34, 35] 
it could be this interaction between the different infections and the host immune system 
which primes, and / or stimulates, the lungs to develop asthma.  
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4.  The difference between poorly controlled asthma and asthma 
exacerbations 
The most commonly used definition of an asthma exacerbation requires not an event 
of a particular character but the management of it – whether that be hospitalisation, 
emergency room presentation or a course of oral corticosteroids. Such an exacerbation can be 
an extension of the pattern of disease in ongoing poor control or an independent event. It is 
clear that some patients have excellent current control of asthma with minimal or no 
symptoms and yet have sudden and severe exacerbations. Viral infections have been 
implicated in such events. At the other extreme, some patients have unrecognised or 
ineffectively managed asthma and have extreme variability in symptoms and lung function. 
In these cases, exacerbations may be recorded not necessarily for the deepest fluctuations in 
lung function, or for specific patterns of asthma worsening, but for those occasions where 
medical advice was sought and treatment given.  
One particularly challenging aspect of asthma exacerbations is the differentiation 
between inadequate treatment regimens leading to episodic symptomatic asthma and 
catastrophic failures in asthma control in response to various stimuli i.e. an exacerbation.  
It can be argued that when medication regimens are not titrated according to objective 
features of asthma, insufficient treatment is delivered. Insufficient treatment may provide 
some benefits to the asthmatic patient in terms of reduced symptoms, however, as 
inflammation and airway hyperresponsiveness are likely to not be fully controlled, this may 
allow exacerbations to occur. The difference between poorly controlled asthma and asthma 
exacerbations is further compounded by the diversity of symptom severity or physiological 
measurements which are used by researchers to describe an exacerbation, and the fact that 
patients are often noncompliant with therapeutic regimens. However, in the general 
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community, asthma treatment guidelines and action plans do provide optimal treatment for 
asthmatic patients, and in clinical trials, in which medication usage is monitored and adjusted 
according to symptoms, exacerbations still occur.    
5.  Can current therapeutic regimens prevent virus induced 
exacerbations? 
There is no doubt that the reductions observed in asthma morbidity and mortality 
observed over the last 20 years are the result of better therapeutic management, however the 
real question is are asthma therapeutics effective in virus-induced exacerbations? Large 
studies have shown that even low dose inhaled corticosteroids (ICS) reduce exacerbations 
and the risk of death from asthma [36]. For example, in comparison to no treatment, 100ug 
budesonide twice daily resulted in a 60% reduced risk of having a severe exacerbation in the 
OPTIMA trial [37]. The addition of long-acting β2-agonist (LABA) to ICS further reduces 
the frequency [38] severity and duration [39] of exacerbations. Studies such as these were not 
designed to identify the cause of the exacerbation, however as viruses are thought to cause at 
least 50% of all exacerbations, it is reasonable to assume that some reduction in the incidence 
of virus-induced exacerbations would occur. None of these studies specifically identifies 
whether improved asthma management does one or more of the following  
1. Reduces the rate of respiratory viral illnesses 
2. Reduces the rate at which respiratory viral infections trigger a sequence of 
inflammatory events that will result in an exacerbation 
3. Reduces the severity of symptoms or lung function such that the episode does not 
require exacerbation-defining medical intervention 
In a prospective multicenter study of 413 asthmatics, Walter et al aimed to determine 
factors which would predict loss of asthma control following a cold. In their study there was 
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no association between the use of ICS with or without β2-agonists and loss of asthma control 
[40]. The severity or number of previous colds was also not associated with loss of asthma 
control, but the severity of the first two days of the current cold could be used to predict loss 
of asthma control. If we were to assume that all viruses are equal, i.e. have the same 
pathogenicity, it would be likely that other co-factors would precipitate the exacerbation, 
however not all viruses are equal. As shown by Wark et al, even serotypes of the same virus 
can have dramatically different innate immune responses in-vitro [41]. There is emerging 
evidence suggesting that the recently described group of rhinoviruses, rhinovirus C, appears 
to cause more severe infections in-vivo, at least in children [42, 43]. This may not be the case 
for adults [44]. This suggests that the gene-environment hypothesis (where the role of any 
given gene is determined by the environment) can now be extended to include the gene virus 
hypothesis, where the interaction of the specific virus and the host immune response will 
dictate whether an exacerbation occurs or not.   
6.  Are corticosteroids effective or ineffective during virus-related 
infections? 
Corticosteroids are known to improve asthma symptoms and decrease exacerbations, 
however virus-induced exacerbations can occur in ICS-treated asthma in patients who are 
well controlled [3]. Clearly, a component of specific virus-induced inflammation is not 
controlled by stable ICS therapy. Whether ICS have no effect on virus-induced asthma 
deterioration is much less clear. In patients using budesonide/formoterol maintenance and 
either terbutaline, formoterol or formoterol/budesonide as reliever, the exacerbation rate after 
onset of reported ‘cold’ symptoms was reduced by as needed budesonide/formoterol 
compared to as-needed formoterol reliever [45]. Even in that setting, there is potential 
confounding by an effect of the additional as needed ICS on residual eosinophilic airway 
inflammation rather than viral mechanisms.  
 12 
In-vitro, we and others have found that steroids inhibit rhinovirus [46-48] and 
respiratory syncytial virus induced cytokine release, supporting the notion that the use of 
steroids in-vivo would suppress virus-induced inflammation.  Interestingly, data from in-vitro 
studies have suggested that the timing of administration of steroids has profound effects upon 
their ability to inhibit virus-induced cytokines.  For example, in bronchial epithelial cells 
,rhinovirus-induced CXCL-10 was inhibited by budesonide when the drug was given at the 
start of the infection period [49], but not when applied 24 hours prior to infection [50].  Quite 
how these in-vitro results translate into clinical practice is uncertain.  It is clear that patients 
with asthma who have poor adherence to medication regimens (for a review see [51]) have 
worse asthma related outcomes, but this is perhaps an extreme example of incorrect 
medication usage.   
Recent in-vitro studies have revealed a molecular mechanism of corticosteroid 
resistance in rhinovirus infected cells [52].  Corticosteroid resistance is often misinterpreted 
as a complete lack of response to corticosteroids, rather than the correct meaning of reduced 
efficacy of the corticosteroids.  So to achieve a desired level of inhibition in the context of 
corticosteroids resistance, it is necessary to increase the dose, bearing in mind that maximal 
effect might never be achieved.  With traditional fixed dose treatment regimens, 
inflammatory states that cause corticosteroid resistance are of particular concern, because if 
the dose of steroid remains constant, this may be insufficient to control inflammation.  In 
theory, this could be overcome by increasing the dose of steroid as part of an asthma 
management plan, yet clinical evidence is lacking to support this approach in either children 
or adults  [53]. An age–related effect may also exist, and may reflect the underlying nature of 
the inflammation. In pre-schoolers with viral-induced wheeze exacerbations, no beneficial 
effect of routine oral corticosteroid use has been shown, either parent-initiated [54] or 
physician-initiated once in the emergency department [55]. High dose ICS (750 microgram of 
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fluticasone propionate twice daily) from the start of a viral illness has, however, been shown 
to reduce the subsequent need for OCS, but attractiveness of this approach was tempered by a 
detrimental effect on growth [56]. In older children the beneficial effect of OCS in these 
settings [57, 58] may in part reflect a greater role for non-viral inflammatory aetiologies (e.g. 
eosinophilic due to allergic triggers). As required (prn) use of combination inhalers 
containing a fast onset long acting bronchodilator and steroid are now beginning to used in 
clinical practice to treat adults with asthma, replacing the combination of short acting 
bronchodilators and a separate corticosteroid based inhaler, however there is not enough 
evidence to suggest this is beneficial in comparison to traditional stepwise up-titration of 
steroid dose [59].   
 Corticosteroid resistance may occur in the context of viral infections, and may 
contribute to the occurrence of an exacerbation.  In most clinical trials measuring the efficacy 
of steroids ± bronchodilators, the general observation is that asthma control is increased by 
the actions of steroids, and is further increased by the addition of bronchodilators.  However, 
even in these carefully carried out and monitored clinical trials, exacerbations still occur.  
The best example of this phenomenon is the study by Reddel et al [3] previously described.  
In that study there is clear evidence that despite asthma being well controlled by steroids, 
exacerbations occur in the context of colds. If we now focus upon experimental infection 
models in human asthma, no reduction in rhinovirus-induced inflammation has been 
observed when using a fixed dose of inhaled steroid [60, 61].  Furthermore, even oral 
prednisone has been shown to be ineffective in controlling rhinovirus-induced asthma 
symptoms [62], and moreover to increase viral titres [63] 
.  When the dose of ICS used in asthma is considered, there is no benefit from doubling 
ICS dose for treatment of exacerbations [64, 65], and this approach is now considered 
insufficient for the management of asthma [66]. A recent study by Oborne et al extended this 
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finding and evaluated the efficacy of quadrupling the usual dose of ICS at the first symptoms 
of a cold however this approach did not reduce exacerbations in comparison to placebo [67].  
Taken together, these studies suggest that corticosteroids should provide some 
immunosuppression in the context of respiratory viral infections, but it is likely that they do 
not fully inhibit virus-induced inflammation or symptoms.   They therefore fail to stop the 
occurrence of virus-induced exacerbations or reduce their severity below the threshold where 
medical attention is sought and treatment given.  
7.  Do respiratory viral infections reduce β2-agonist efficacy? 
Reddel et al provided the first objective evidence for loss of β2-agonist efficacy in asthmatics 
with a cold [3]. In their study, peak expiratory flow was monitored in asthmatics both prior to 
and post treatment with the ICS budesonide. Prior to ICS treatment, peak expiratory flow had 
characteristically high diurnal variation, and, following ICS treatment, good asthma control 
was reflected by increased peak expiratory flow and decreased variability. In the study 
volunteers, even though good asthma control had been achieved, 39 exacerbations associated 
with clinical colds occurred. In these, peak expiratory flow declined and recovered over 7-14 
days. Importantly post-β2-agonist and evening peak flow values were no higher than pre-β2 
agonist and morning values, implying impaired response to β2-agonist. During these 
exacerbations, diurnal variability was not significantly different from that observed during 
good asthma control. This study provides evidence that viral exacerbations have different 
pathophysiological mechanisms in comparison to untreated or poorly-controlled asthma. One 
of the proposed mechanisms by which virus infections limit the action of β2-agonist is via the 
production of mucus [68]. Whilst it is possible that increased mucus in the airway lumen 
following virus infection could impair β2-agonist efficacy by reducing the amount of drug 
reaching the smooth muscle, β2-agonists have clinical benefit in respiratory diseases with 
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abnormal mucus production such as cystic fibrosis [69, 70] and COPD [71]. It is therefore 
likely that viral infection of the airway may affect the inherent ability of the airway smooth 
muscle to respond to β2-agonists. A second proposed mechanism to explain the lack of 
response to β2-agonist which occurs during viral infections is the development of tolerance. 
The development of tolerance to β2-agonists can be experimentally demonstrated both in-vivo 
[72], and in-vitro [73], however in the Reddel study above, β2-agonist use was lower during 
viral exacerbations than during the initial period of poor asthma control, and, as such, 
tolerance is unlikely to account for the changes. A third potential mechanism to explain the 
reduced efficacy of β2-agonists during viral infections is the possibility that obstruction 
occurs as a direct result of inflammation.   Inflammation is accompanied by increased 
microvascular leakage and tissue oedema.  Oedema would act to thicken the airway wall, 
therefore decreasing lumen size.  Increased vascular permeability occurs as asthma control 
deteriorates, [74], however oedema is not related to changes in airway hyperresponsiveness 
during allergen challenges [75].  This finding is supported by studies in animals which have 
found that oedema causes only modest airway narrowing [76].  The exact contribution of 
odema to airway obstruction during virus induced exacerbations is not known, but it is 
perhaps likely not to be the primary cause of reduced airflow. In an attempt to understand the 
mechanisms responsible for the decreased β2-agonist efficacy observed during viral 
infections, we have established an in-vitro model [77] to test the hypothesis that virus 
infection impairs β2AR activation. Since it is now accepted that RV reaches, infects and 
replicates in lower airway epithelium [78], our model uses a co-culture system in which 
epithelial cells are infected with rhinovirus (RV) and conditioned medium is used to treat 
airway smooth muscle cells prior to assessing β2 adrenoceptor function. We chose to use 
rhinovirus as the model virus, since it is responsible for at least half of all virus-induced 
asthma exacerbations. In our study, we observed that β2-agonist induced cAMP was reduced 
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in airway smooth muscle cells that had been treated with conditioned medium from virally 
infected epithelial cells. We propose that this response is specific to replicating rhinovirus, 
since no reduction in β2-agonist induced cAMP occurred in response to conditioned medium 
from epithelial cells treated with UV inactivated virus, poly I:C (a surrogate for other viruses) 
or the bacterial endotoxin lipopolysaccharide. Using flow cytometery we were able to assess 
membrane and total β2 adrenoceptor levels. Following exposure to rhinovirus conditioned 
medium, airway smooth muscle cell surface, but not total, β2 adrenoceptor number was 
reduced, suggesting that desensitisation of the β2 adrenoceptor had occurred. In recent studies 
we have identified the mechanism by which desensitisation occurs [79]. Rhinovirus 
replication in epithelial cells is not perfect, and in addition to progeny, viral particles and 
unpackaged viral RNA are also released from infected cells [80, 81]. We took the cell culture 
supernatant from rhinovirus-infected primary bronchial epithelial cells and were able to 
detect viral RNA.  We purified the viral RNA, and, as a control, used human mRNA, and 
used both to stimulate airway smooth muscle cells.  We found that only viral RNA  
stimulated prostaglandin release from airway smooth muscle cells.  As depicted in figure 1, 
the prostaglandins acted through an autocrine mechanism to cause β2 adrenoceptor 
desensitisation . Reduced total cellular expression of the β2 adrenoceptor has also been shown 
to occur in-vitro when airway smooth muscle cells are directly infected with respiratory 
syncytial virus [82]. This study is interesting but caution has to be observed when examining 
the direct effect of viral infection upon a cell. Viruses subvert the host machinery in order to 
manufacture progeny viruses, and, in turn, the cell attempts to apoptose to limit viral spread. 
As such it would be important to show specific down regulation of a given receptor, rather 
than a global downregulation prior to apoptosis.       
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8.  Leukotriene receptor antagonists 
For many years leukotrienes have been suggested to be important in the pathology of virus-
induced exacerbations, however there is a marked paucity of in-vivo and in-vitro studies 
exploring this hypothesis. Respiratory tract viral infection upregulates 5-lipoxygenase in the 
bronchial mucosa [83], an enzyme needed in the cellular production of leukotrienes. Elevated 
leukotriene C4 is found in nasal lavage fluid post experimental infection with either 
rhinovirus, or respiratory syncytial virus, or influenza A virus [84], thus providing some 
evidence for the potential involvement of leukotrienes in virus-induced exacerbations. 
Targeted therapy such as the leukotriene receptor antagonist monteleukast, when used as 
monotherapy, has been shown to be only modestly effective during respiratory tract infection 
induced wheeze [85], but it is important to note that, in the same study, monteleukast had 
similar efficacy to ICS. Furthermore, in a randomised double blinded placebo controlled trial, 
the addition of monteleukast to usual therapy resulted in a 53% reduction in days with worse 
asthma symptoms compared with placebo and a 78% reduction in unscheduled physician 
visits for asthma [86]. However the exact nature of the involvement of leukotrienes in the 
pathogenesis of rhinovirus and other respiratory viral infections is controversial. For 
example, in an experimental rhinovirus infection model, monteleukast had no effect upon 
rhinovirus-induced colds or asthma symptoms [87].  Monteleukast has also been found not to 
affect respiratory symptoms post RSV-bronchiolitis  [88, 89], or the incidence of upper 
respiratory tract infections [90].  
9.  Clues from virus-induced inflammation  
The immune response to naturally acquired respiratory viral infections is complicated due to 
the heterogeneity of responses observed between different virus genotypes and serotypes, the 
effects of concurrent environmental stimuli, and pharmacotherapy. One approach to 
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overcome such confounders is to experimentally infect volunteers. Experimental rhinovirus 
infections can induce asthma exacerbations [91], and reduce the peak expiratory flow in both 
asthmatic [92] and non-asthmatic [93] subjects. 
Airway eosinophilia is a characteristic of asthma, and many reports exist showing the 
relationship between eosinophil activation and recruitment in rhinovirus infected asthmatic 
volunteers. Given the correlation between increased airway hyper-responsiveness and 
eosinophil recruitment and activation, for example as assessed by eosinophil cationic protein 
levels [94], it is tempting to speculate causality. However an increase in eosinophil numbers 
[94, 95]has not been found in all human experimental rhinovirus infection studies Mouse 
models of rhinovirus exacerbations against a  background of OVA-induced allergic airways 
disease exhibit increased airways hyperresponsiveness accompanied by increased eosinophil 
numbers [96].  Interestingly, in such models, the development of airways 
hyperresponsiveness is inhibited by the administration of anti-eotaxin-1 [97].  However in the 
context of the murine model of house-dust-mite induced allergic airways disease,  rhinovirus 
infection does not induce eosinophilia [98].  The contrasting results from the two mouse 
models perhaps tell us more about the utility of the models [99], than the putative role of the 
eosinophil. In animal models of RSV and Sendai (parainfluenza) infection, eosinophils have 
been found to be important in viral clearance [100] [101] raising the possibility that 
eosinophilic inflammation is beneficial under certain circumstances. 
The role of the eosinophil in asthma is complex.  For example, in people with severe 
asthma treated with corticosteroids, the presence of eosinophilia is associated with more 
frequent exacerbations [102].  In such populations treatment with mepolizumab (anti-IL-5) 
reduces both the number of eosinophils and exacerbations[103] .  In steroid responsive 
asthma, airway eosinophilia is reduced by ICS, and, it is this fact that has enabled 
eosinophilia to be used as a biomarker to assess optimal ICS treatment [104] 
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It is our view that virus-induced eosinophilia is unlikely to account for the failure of 
asthmatic treatment regimens during virus-induced exacerbations.. In contrast, the role of the 
neutrophil in both the aetiology and pathogenesis of asthma is unclear. Rhinovirus infection 
increases circulating and bronchial lavage neutrophils in asthmatic volunteers [105], and both 
neutrophil number and the neutrophil chemokine IL-8 negatively correlate with airway 
function [106, 107] in experimentally infected volunteers. The relationship between 
corticosteroid use/efficacy and neutrophilic inflammation is potentially confounded as 
corticosteroids reduce airway eosinophilia (and therefore increase the proportion of 
neutrophils) and inhibit neutrophil apoptosis. However in a study of 205 patients, 
multivariate linear regression has shown no association of airway neutrophilia with 
corticosteroid use [108], and airway neutrophilia occurs in asthmatic patients who are 
corticosteroid naïve [109]. In the absence of acute infection, the presence of airway 
neutrophilia is associated with steroid insensitive asthma [109], therefore virus-induced 
neutrophilia could represent the steroid insensitive component of virus induced 
exacerbations.  As such, virus-induced neutrophilia deserves further consideration.  
The exact role of neutrophils during virus infections of the lung and the ensuing 
asthma exacerbation is not known, largely because existing therapies for asthma do not 
directly target neutrophils. PDE4 inhibitors (PDE4i) as used in COPD, and a newer 
experimental class of therapy CXCR2 (CXCL8 receptor) antagonists, offer some insights. 
PDE4i are a relatively new class of anti-inflammatory medication and their main mechanism 
of action is to suppress lung neutrophilia in-vivo (for a review see [110]). In COPD, where 
50% of exacerbations are caused by rhinovirus, PDE4i reduced exacerbation frequency [111], 
suggesting neutrophilia is an important component of exacerbations. PDE4i were developed 
as a refinement to theophylline, a pan PDE inhibitor, and like theophylline have anti-
inflammatory properties. In contrast to theophylline, PDE4i such as roflumilast, do not have 
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direct bronchodilator activity [112], perhaps because direct bronchodilation is mediated 
through other PDEs such as PDE3 [113], however the role of other PDEs in direct 
bronchodilation needs to be verified. We and others have shown that in-vitro PDE4 is the 
main PDE which degrades β2-agonist-induced cAMP, and furthermore we found the activity 
of PDE4 to be increased in airway smooth muscle from people with asthma [114].  Whether 
increased PDE4 in asthma equates to an increased susceptibility to β2-adrenoceptor 
desensitisation remains to be determined.   Preclinical models have found that 
bronchodilation induced by low dose salbutamol is enhanced in the presence of PDE4 
inhibitors [115], raising the possibility that the reduction in exacerbation frequency observed 
in patients with COPD treated with roflumilast may in part be mediated by increased or 
sustained efficacy of β2-agonists.  CXCR2 antagonists are still in development, but a recent 
publication has shown that one of them-SCH527123 is safe, and importantly reduces 
exacerbations of asthma [116].  It is likely that these therapies work via suppression of  the 
accumulation of neutrophils, presumably showing that the existing lung neutrophils are 
sufficient to combat the infection. 
We [117] and others have shown that rhinovirus infection induces lung neutrophilia in 
murine models, but there are no studies which specifically examine the role of neutrophils in 
the context of an asthma exacerbation. Nagarkar et al used a series of knockout mice and 
elegantly demonstrated that neutrophil derived TNF-α is critical for the development of 
airways hyper-reactivity [118]. They did not investigate which cells were responsible for 
neutrophil chemokine production or if inhibition of neutrophil influx affected either the 
number of infectious virions or the clearance of rhinovirus. 
Conventionally, exhaled nitric oxide is thought to reflect airway eosinophilia and is 
advocated as a biomarker to assess asthma control [119]. However new evidence regarding 
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the role of nitric oxide in the airways is emerging and it is too simplistic to consider it as a 
simple marker of inflammation. Exhaled nitric oxide is increased in people without asthma 
with naturally acquired upper respiratory tract infections [120], and  is also elevated 
following experimental rhinovirus infection [121]. In-vitro, nitric oxide inhibits rhinovirus 
replication and cytokine production [120], and the replication of influenza [122] and 
respiratory syncytial virus[123], suggesting that it is likely to be important in virus-induced 
exacerbations.  Importantly, in asthmatic volunteers who were experimentally infected with 
rhinovirus, the production of nitric oxide was negatively correlated with airway 
hyperresponsiveness to histamine [124], ie the production of nitric oxide was protective. 
Nitric oxide may represent a paradox in the context of viral infections and treatment with 
ICS. ICS are well known to inhibit exhaled nitric oxide, however if nitric oxide limits virus 
replication, and, therefore presumably virus-induced inflammation, reduced nitric oxide by 
ICS would be detrimental. Further research is needed to elucidate the role of virus-induced 
nitric oxide in-vivo.  
 
10. The host response to virus infection 
The host response to virus infection is complex, and dependent upon a number of 
variables such as the type and amount of virus, the immunocompetency of the host, and 
underlying disease pathology.   Given this complexity, and given the importance of 
rhinovirus infection as a precipitant of asthma exacerbations, the following section discussing 
the host’s response to viral infection is mainly focused upon the response to rhinovirus.    
Rhinoviruses are relatively simple viruses.  They have a single strand of positive 
sense RNA which is packaged into an iscohedral capsid, formed by 3 different viral proteins, 
whilst a fourth viral protein is found on the interior of the capsid and is in contact with the 
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viral RNA [125].  They are classified according to molecular traits, being defined as species 
A, B or C.  Species A mainly consist of viruses that infect cells via low density lipoprotein 
(LDL) receptor family, species B via ICAM-1, whilst the receptor for species C is unknown.    
The initial innate immune response to rhinovirus infection is considered to occur once 
the virus RNA has been delivered into the cytoplasm, as part of the infection process, and is 
recognised by pattern recognition receptors.  However, several studies using UV-irradiated 
virus, which is incapable of replication, have suggested that binding to the receptor alone 
elicits similar responses to replication competent (live) rhinovirus [126-130].  Interestingly, 
UV-irradiated rhinovirus has been found to be inert in a number of similar studies [131-134].  
There are several potential explanations for the observed differences, and the most likely in 
our opinion relates to differences in the amount of UV-irradiation.  When UV-irradiation is 
insufficient, virus replication can occur, and when too much UV-irradiation is used, the viral 
capsid is either partially or totally destroyed, making any interaction with cellular receptors 
very unlikely.   
Rhinovirus is a single stranded RNA virus, and during replication, a double stranded 
intermediate is formed, which is detected by different intracellular receptor families.  Single 
stranded viral RNA is recognised by both Toll-like receptor (TLR) 7 and 8, whilst double 
stranded RNA is detected by TLR-3 and the RNA helicases, retinoic acid inducible gene 
(RIG-I) and melanoma differentiation associated gene-5. Whilst opposing conclusions 
regarding the importance of the two recognition systems have been found in different studies, 
it is likely that both receptor systems are important in eliciting the host’s response to 
rhinovirus infection [135, 136].   
Regardless of the exact cellular process used to detect a virus, the net result of 
detection is activation of the innate anti-viral immune response, characterised by the robust 
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induction of a plethora of pro-inflammatory cytokines, chemokines and anti-viral mediators.  
This increased inflammation forms the basis of the prevailing hypothesis as to why viral 
infections cause asthma exacerbations.  However, the million-dollar question is why does this 
increase in inflammation cause some people with asthma to experience an exacerbation, and 
others not to? One theory that has been put forward is exacerbations occur in those with 
dysfunctional innate immunity. 
 No discussion on virus-induced inflammation would be complete without reference to 
the potential deficits in innate immunity in asthma. In 2005, the first of a series of studies 
from the UK demonstrating impaired rhinovirus-induced type I interferons in asthmatic 
epithelial cells in-vitro was published [134]. This was followed by a similar study showing 
deficient rhinovirus-induced type III interferons [137]. As depicted in figure 2, the 
importance of these findings lies in the fact the type I and III interferons induce apoptosis and 
therefore limit virus replication.  These publications sparked a flurry of research in the area, 
often with mixed results. Lopez-Souza et al used a more complex in-vitro model with 
differentiated epithelial cells [138]. In their study no differences in the production of 
rhinovirus induced type I interferon was found. There is no obvious explanation for the 
discrepancy, and it is likely that differentiated epithelial cells produce different amounts of 
cytokines in comparison to undifferentiated cells making the differences in the outcomes of 
the two studies difficult to interpret. However, other researchers have also not found 
differences in type I and III interferons between asthma and non-asthma in response to 
rhinovirus infection both in-vitro [139]  and in-vivo [140].  Similarly no difference in 
interferon production has been observed in response to infection with either respiratory 
syncytial virus or human metapneumovirus [141].  Interestingly, the group which initially 
reported impaired interferon production in response to rhinovirus infection in asthmatic 
epithelial cells has recently reported no differences in interferon production [142].  In their 
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discussion of the potential reasons for the discrepant results, differences in underlying disease 
severity and or degree of airways inflammation are suggested as potential confounders.  The 
weight of evidence suggests that deficient interferon production from asthmatic bronchial 
cells as a general concept is unlikely to occur, however it remains to be seen if it is a feature 
of specific asthma phenotypes.  
Irrespective of whether asthmatic cells release fewer type I or III interferons or not, 
the important question is do ICS affect the production of type I or III interferons? In-vitro, in 
our laboratory we have found that the corticosteroids dexamethasone and fluticasone do not 
affect rhinovirus replication in primary lung cells [47], and there is good evidence to suggest 
that corticosteroids do not affect virus-induced type I interferons [134].  
11.  The role of secondary or co-infection in virus induced 
exacerbations.  
Other pathogens have co-evolved with viruses and are able to utilize the window of 
opportunity created by viral infection and superinfect the host [143]. For example, it is well 
known that the rate of bacterial infection increases during episodic viral pandemics [144]. 
One mechanism by which superinfection occurs is by increased binding and retention of 
bacteria to the respiratory epithelium [145-148]. Furthermore, we have also shown that the 
innate immune response to bacteria is markedly impaired in virally infected alveolar 
macrophages [149] . In comparison to other diseases and pathogens, the role of bacterial 
infections in asthma exacerbations is controversial. However asthmatics have increased 
susceptibility to invasive bacterial infection [150], and atypical bacterial infection has been 
reported to be  reactivated in virus induced asthma exacerbations [151] and related to 
exacerbation frequency [152].  There is also evidence that macrolide antibiotics, when used 
prophylactically[153, 154], or after the occurrence of an acute exacerbation[155] are effective 
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treatments for asthma  If bacteria are co-conspirators in virus-induced exacerbations, it is 
highly likely that the exacerbation would not respond to ICS and β2-agonists, as these drugs 
would not inhibit bacterial growth. Further research is needed in this area to fully describe the 
role of bacteria in virus induced exacerbations.  
12.  A role for allergens in rhinovirus induced exacerbations of 
asthma 
Whilst there is little doubt that both exposure to allergens and viral infections can induce 
asthma exacerbations, there is surprisingly little information regarding their interaction. It has 
proven to be very difficult to document personal allergen exposure leading to an exacerbation 
of asthma except in rare events such as thunderstorms [156][157], and perhaps this is the 
reason why very few reports document the interaction between naturally acquired viral 
infections and allergen exposure in asthma exacerbations. Green and others (2002) provide 
evidence for synergism between virus infections and allergen exposure [158]. In their case 
controlled study, the risk of being admitted to hospital was considerably increased by 
exposure to high levels of antigen and concurrent viral infection.  This finding is supported 
by other studies that have measured the amount of IgE, and often specific IgE, to establish if 
any relationships exist between IgE levels and the likelihood of a virus induced exacerbation.  
The first of this series of studies found the odds ratio for virus-induced wheeze in children 
over two attending the emergency department was 4.4 if a rhinovirus was detected.  The 
concomitant presence of specific IgE increased the odds ratio to 17, and was higher if nasal 
eosinophilia or elevated nasal ECP was present (odds ratios of 21 and 25 respectively) [159].  
This relationship may be specific to rhinovirus and not other viruses [160], and furthermore 
other studies indicate that rhinovirus C may be an important precipitant of exacerbations 
under such circumstances [161].  Systematic reviews have shown anti-IgE (Omalizumab) to 
reduce exacerbations in children and adults with asthma [162], and in an elegant study by 
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Busse et al, omalizumab  [163] was shown to reduce exacerbations in spring and autumn 
further providing evidence for the interaction between IgE and virus-induced asthma 
exacerbations.  Such studies provided the basis for experimental studies in humans. The 
sequence of events is likely to affect the experimental outcomes, however regardless of the 
sequence of exposure to allergen and viral infection, both stimuli have been shown to affect 
the subsequent response to the other. Experimental rhinovirus infection increases eosinophil 
recruitment into the lower airways, and the occurrence of a late phase response to allergen 
[164, 165]. Antigen exposure followed by experimental rhinoviral infection one month later 
also induced a late phase asthmatic response [166]. Whilst changes can be observed in lung 
function parameters, in contrast, modulation of the immune response in terms of cytokine and 
chemokine induction is not altered by antigen exposure prior to rhinovirus infection.  This is 
based on the fact that nasal IL-6 and IL-8 levels were not altered by antigen or placebo 
exposure prior to rhinovirus infection [167]. Similarly, lower airway IL-8 production was not 
further increased by prior repetitive exposure to low dose house dust mite allergen [92].      
13.  How could we stop virus-induced exacerbations  
As described above and shown in figure 1, virus-induced asthma exacerbations are likely to 
involve multiple mechanisms, and, as such, a single treatment modality is unlikely to be 
effective in all people with asthma. In order to completely stop virus induced exacerbations 
from occurring, good asthma management would have to be implemented prior to a second 
prophylactic treatment strategy. Due to the cost and potential side effects of prophylactic 
treatment, it would be necessary to identify those who are at risk of a virus-induced 
exacerbation on a background of good asthma control, perhaps by close monitoring of their 
asthma or through the use of biomarkers. One such potential biomarker is IFN-gamma-
induced protein 10 (IP-10). Wark et al have shown that virus-induced exacerbations are 
associated with approximately 4 fold higher serum IP-10 in comparison to non viral 
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exacerbations [168].  An alternative strategy would be to predict when virus induced 
exacerbations are likely to occur, for example at times of the year when children return to 
school, so prophylactic treatment could be implemented seasonally. Of course, the ideal 
approach would be to eradicate respiratory viruses, however, realistically, this approach is not 
feasible. It is possible to immunize against both RSV [169] and influenza [170] but these are 
likely to provide “immunity” against only certain serotypes of virus, and will not actually 
stop infection from occurring. Whilst it is not possible to vaccinate against rhinovirus, this 
approach is being currently evaluated [171]. Anti-rhinovirals are being developed [172] 
[173], and are available for both RSV and influenza.  The efficacy of such antiviral strategies 
in terms of preventing asthma exacerbations is not known 
14.  Perspective  
In this century, our understanding of the relationship between virus infections and 
asthma has greatly expanded but is incomplete. This must be greatly expanded by studies in 
volunteers using bronchoscopic biopsies and biomarkers[106]. Future studies should evaluate 
the role of different viruses and virus serotypes of the same virus and how effects are 
modulated by pre-existing asthma phenotype. Understanding basic mechanisms is necessary 
so that, armed with this knowledge, we can be aware of which aspects of infection are 
sensitive and resistant to current treatments. From that position, we can evaluate the effect of 
novel strategies and pharmacotherapies on virus-induced asthma exacerbations.  
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Figure 1. Rhinovirus-induced β2-adrenoceptor desensitisation.  A) Inhibition of COX restores 
β2-adrenoceptor function in airway smooth muscle cells treated with conditioned medium 
from rhinovirus infected epithelial cells (data redrawn from 84).  B) A cartoon of the 
proposed mechanism of β2-adrenoceptor desensitisation: 1 – Rhinovirus infects epithelial 
cells and replicates releasing progeny virions and (2) viral RNA.  The viral RNA is detected 
by airway smooth muscle cells (3) and stimulates the production of prostaglandins (4).  These 
prostaglandins act in an autocrine manor (5) to cause β2-adrenoceptor desensitisation (6) 
Figure 2.  A cartoon illustrating the role of interferons in limiting virus infection. 
Figure 3. A cartoon depicting the consequences of viral infection, and an indication as to 
whether these are likely to respond to current therapy.  
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